ATE459359T1 - Verwendung von kondensierten heterozyklischen verbindungen als scce-hemmern zur behandlung von hautzuständen - Google Patents
Verwendung von kondensierten heterozyklischen verbindungen als scce-hemmern zur behandlung von hautzuständenInfo
- Publication number
- ATE459359T1 ATE459359T1 AT04736195T AT04736195T ATE459359T1 AT E459359 T1 ATE459359 T1 AT E459359T1 AT 04736195 T AT04736195 T AT 04736195T AT 04736195 T AT04736195 T AT 04736195T AT E459359 T1 ATE459359 T1 AT E459359T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- heterocyclic compounds
- skin conditions
- condensed heterocyclic
- scce
- Prior art date
Links
- 102100034867 Kallikrein-7 Human genes 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 101710176222 Kallikrein-7 Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Cosmetics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300840 | 2003-06-06 | ||
| DKPA200300843 | 2003-06-06 | ||
| DKPA200300842 | 2003-06-06 | ||
| DKPA200300844 | 2003-06-06 | ||
| PCT/DK2004/000388 WO2004108139A2 (en) | 2003-06-06 | 2004-06-07 | Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE459359T1 true ATE459359T1 (de) | 2010-03-15 |
Family
ID=33514772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04736195T ATE459359T1 (de) | 2003-06-06 | 2004-06-07 | Verwendung von kondensierten heterozyklischen verbindungen als scce-hemmern zur behandlung von hautzuständen |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7872052B2 (de) |
| EP (1) | EP1631295B1 (de) |
| JP (1) | JP5044214B2 (de) |
| KR (2) | KR101099409B1 (de) |
| CN (1) | CN101152185B (de) |
| AT (1) | ATE459359T1 (de) |
| CA (1) | CA2525383C (de) |
| CY (1) | CY1110084T1 (de) |
| DE (1) | DE602004025803D1 (de) |
| DK (1) | DK1631295T3 (de) |
| ES (1) | ES2341545T3 (de) |
| NO (1) | NO20060091L (de) |
| NZ (1) | NZ543636A (de) |
| PL (1) | PL1631295T3 (de) |
| PT (1) | PT1631295E (de) |
| SI (1) | SI1631295T1 (de) |
| WO (1) | WO2004108139A2 (de) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| US8044060B2 (en) | 2003-05-09 | 2011-10-25 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory |
| DE10320785A1 (de) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
| DE102004001873A1 (de) | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
| JP5368792B2 (ja) * | 2005-07-29 | 2013-12-18 | レスバーロジックス コーポレイション | 複合疾患の予防および処置のための薬学的組成物および挿入可能な医療用デバイスによるその送達 |
| CN101535304A (zh) | 2006-09-21 | 2009-09-16 | 埃迪威克斯生物科学公司 | 丝氨酸水解酶抑制剂 |
| CA2663436A1 (en) | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| DK2118074T3 (en) | 2007-02-01 | 2014-03-10 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
| JP5401459B2 (ja) * | 2007-08-17 | 2014-01-29 | ノバルティス アーゲー | カリクレイン７を阻害するための環状デプシペプチドの使用 |
| MX2010001849A (es) | 2007-08-17 | 2010-03-10 | Novartis Ag | Depsipeptidos ciclicos. |
| JP5498392B2 (ja) | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CN102143965A (zh) | 2008-09-08 | 2011-08-03 | 贝林格尔.英格海姆国际有限公司 | 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途 |
| NZ594332A (en) | 2009-01-08 | 2013-09-27 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular disease |
| EP2403857B1 (de) * | 2009-03-05 | 2013-12-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidine als cdc7 kinase inhibitoren |
| KR101709492B1 (ko) | 2009-03-18 | 2017-02-23 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| PT2414363E (pt) | 2009-03-31 | 2014-02-26 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| TWI419884B (zh) * | 2010-06-24 | 2013-12-21 | Univ Chang Gung | 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物 |
| UA110347C2 (uk) | 2010-08-12 | 2015-12-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| AR086168A1 (es) | 2011-04-20 | 2013-11-27 | Novartis Ag | Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios |
| US8680054B2 (en) | 2011-04-20 | 2014-03-25 | Novartis Ag | Suspension type topical formulations comprising cyclic depsipeptide |
| RU2640115C2 (ru) | 2011-11-01 | 2017-12-26 | Ресверлоджикс Корп. | Фармацевтические композиции замещенных хиназолинонов |
| TW201341367A (zh) | 2012-03-16 | 2013-10-16 | Axikin Pharmaceuticals Inc | ３，５－二胺基吡唑激酶抑制劑 |
| LT3495367T (lt) | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9067978B2 (en) | 2012-10-09 | 2015-06-30 | Novartis Ag | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| US8987413B2 (en) | 2012-10-09 | 2015-03-24 | Novartis Ag | Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| PT3097085T (pt) * | 2014-01-23 | 2020-10-08 | Sixera Pharma Ab | Derivados de benzoxazinona para tratamento de doenças de pele |
| EP3097084B1 (de) * | 2014-01-23 | 2020-09-30 | Sixera Pharma AB | Neue kallikrein-7-inhibitoren |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| HUE049801T2 (hu) | 2014-12-23 | 2020-10-28 | Sma Therapeutics Inc | 3,5-diaminopirazol kináz inhibitorok |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| SG11201706287PA (en) | 2015-02-20 | 2017-09-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019074981A1 (en) * | 2017-10-09 | 2019-04-18 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CN108421034A (zh) * | 2018-04-24 | 2018-08-21 | 济南磐升生物技术有限公司 | 激肽释放酶7在皮肤创伤愈合中的应用 |
| ES3061844T3 (en) | 2018-05-04 | 2026-04-07 | Incyte Corp | Salts of an fgfr inhibitor |
| MX2020011718A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas. |
| TWI803696B (zh) | 2018-09-14 | 2023-06-01 | 日商橘生藥品工業股份有限公司 | 次黃嘌呤化合物 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2020210375A1 (en) | 2019-04-09 | 2020-10-15 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL291398B2 (en) | 2019-10-01 | 2025-05-01 | Molecular Skin Therapeutics Inc | Benzoxazinone compounds as dual inhibitors of KLK5/7 |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP7502945B2 (ja) * | 2020-09-08 | 2024-06-19 | 花王株式会社 | デリケートエリアのかぶれの検査方法 |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| CN117396188A (zh) | 2021-06-01 | 2024-01-12 | 西可斯拉制药公司 | 6-乙氧基-7-甲氧基-2-(2-甲基硫基苯基)-3,1-苯并噁嗪-4-酮的水包油乳液 |
| EP4352060A1 (de) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclische heterocyclen als fgfr-inhibitoren |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| CN119768163A (zh) * | 2022-06-21 | 2025-04-04 | 丹娜-法伯癌症研究院 | 稠合双环egfr抑制剂及其使用方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1153994A (en) * | 1965-07-21 | 1969-06-04 | Aspro Nicholas Ltd | Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them |
| FR2121341A1 (en) | 1971-01-04 | 1972-08-25 | Ferlux | 2-substd-3,1-benzoxazin-4-ones - antiinflammatories, analgesics sedatives and diuretics |
| IT1050750B (it) * | 1975-12-05 | 1981-03-20 | Erba Carlo Spa | Derivati della 3.4 di idro chinazolina |
| JPS5576868A (en) | 1978-12-01 | 1980-06-10 | Hisamitsu Pharmaceut Co Inc | Novel 3,1-bezoxazine derivative |
| GB8817651D0 (en) * | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
| HUT58310A (en) * | 1988-12-21 | 1992-02-28 | Upjohn Co | Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them |
| JPH07316056A (ja) * | 1990-02-15 | 1995-12-05 | Teijin Ltd | エラスターゼ阻害用医薬組成物 |
| AU635403B2 (en) * | 1990-02-15 | 1993-03-18 | Teijin Limited | 4h-3,1-benzoxazin-4-one compound and elastase inhibitor composition containing the same |
| EP0525123B1 (de) * | 1990-06-20 | 1997-09-17 | PHARMACIA & UPJOHN COMPANY | Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate |
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| CA2102780C (en) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5346886A (en) * | 1993-11-15 | 1994-09-13 | John Lezdey | Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin |
| AU1375000A (en) * | 1998-11-26 | 2000-06-13 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
| EP1212097B1 (de) * | 1999-09-10 | 2005-11-16 | The Procter & Gamble Company | Enzyminhibitoren |
| ATE515940T1 (de) | 2001-02-09 | 2011-07-15 | Torbjoern Egelrud | Scce transgene mäuse und deren verwendung als modell für menschliche krankheiten |
| AU2002317377A1 (en) * | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| JP4395073B2 (ja) * | 2002-10-03 | 2010-01-06 | 株式会社医薬分子設計研究所 | キナゾリン−４−オン誘導体 |
| US20060052345A1 (en) * | 2002-11-04 | 2006-03-09 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
| PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
-
2004
- 2004-06-07 US US10/559,322 patent/US7872052B2/en not_active Expired - Lifetime
- 2004-06-07 EP EP04736195A patent/EP1631295B1/de not_active Expired - Lifetime
- 2004-06-07 DK DK04736195.1T patent/DK1631295T3/da active
- 2004-06-07 DE DE602004025803T patent/DE602004025803D1/de not_active Expired - Lifetime
- 2004-06-07 CA CA2525383A patent/CA2525383C/en not_active Expired - Fee Related
- 2004-06-07 SI SI200431406T patent/SI1631295T1/sl unknown
- 2004-06-07 PL PL04736195T patent/PL1631295T3/pl unknown
- 2004-06-07 KR KR1020057023349A patent/KR101099409B1/ko not_active Expired - Fee Related
- 2004-06-07 NZ NZ543636A patent/NZ543636A/en not_active IP Right Cessation
- 2004-06-07 WO PCT/DK2004/000388 patent/WO2004108139A2/en not_active Ceased
- 2004-06-07 AT AT04736195T patent/ATE459359T1/de active
- 2004-06-07 KR KR1020117022051A patent/KR101205257B1/ko not_active Expired - Fee Related
- 2004-06-07 PT PT04736195T patent/PT1631295E/pt unknown
- 2004-06-07 CN CN2007101613027A patent/CN101152185B/zh not_active Expired - Fee Related
- 2004-06-07 JP JP2006508134A patent/JP5044214B2/ja not_active Expired - Fee Related
- 2004-06-07 ES ES04736195T patent/ES2341545T3/es not_active Expired - Lifetime
-
2006
- 2006-01-06 NO NO20060091A patent/NO20060091L/no not_active Application Discontinuation
-
2010
- 2010-05-21 CY CY20101100450T patent/CY1110084T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2525383A1 (en) | 2004-12-16 |
| CN101152185B (zh) | 2010-12-08 |
| KR101099409B1 (ko) | 2011-12-27 |
| DK1631295T3 (da) | 2010-06-21 |
| CY1110084T1 (el) | 2015-01-14 |
| WO2004108139A2 (en) | 2004-12-16 |
| DE602004025803D1 (de) | 2010-04-15 |
| PL1631295T3 (pl) | 2010-09-30 |
| HK1091731A1 (zh) | 2007-01-26 |
| JP2006526581A (ja) | 2006-11-24 |
| WO2004108139A8 (en) | 2005-04-28 |
| AU2004244704A1 (en) | 2004-12-16 |
| KR20060008331A (ko) | 2006-01-26 |
| NO20060091L (no) | 2006-03-06 |
| EP1631295B1 (de) | 2010-03-03 |
| PT1631295E (pt) | 2010-05-24 |
| WO2004108139A3 (en) | 2005-03-10 |
| US7872052B2 (en) | 2011-01-18 |
| CN101152185A (zh) | 2008-04-02 |
| CA2525383C (en) | 2012-03-06 |
| SI1631295T1 (sl) | 2010-06-30 |
| US20060258651A1 (en) | 2006-11-16 |
| KR101205257B1 (ko) | 2012-11-27 |
| EP1631295A2 (de) | 2006-03-08 |
| HK1120209A1 (en) | 2009-03-27 |
| KR20110120960A (ko) | 2011-11-04 |
| NZ543636A (en) | 2009-07-31 |
| JP5044214B2 (ja) | 2012-10-10 |
| ES2341545T3 (es) | 2010-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004025803D1 (de) | Verwendung von kondensierten heterozyklischen verbindungen als scce-hemmern zur behandlung von hautzuständen | |
| EA200702048A1 (ru) | Фармакокинетически улучшенные соединения | |
| ATE447574T1 (de) | 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes | |
| ATE373660T1 (de) | Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes | |
| ATE499097T1 (de) | Monozyklische heterozyklen als kinase-hemmer | |
| EA200970050A1 (ru) | Ингибиторы пролилгидроксилаз | |
| DE60310991D1 (de) | Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes | |
| DE60320008D1 (de) | Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes | |
| DE602005022320D1 (de) | Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| EA201000915A1 (ru) | Ингибиторы пролилгидроксилазы | |
| EA200300947A1 (ru) | Арил и гетероарил мочевины в качестве ингибиторов chk1 для использования в качестве радиосенсибилизаторов и химиосенсибилизаторов | |
| TW200510333A (en) | Benzimidazole compounds | |
| EA200601391A1 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
| EA201170344A1 (ru) | Азаиндольные ингибиторы iap | |
| NO20055741L (no) | Nye kjemiske forbindelser | |
| DE60328603D1 (de) | Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren | |
| DE60329326D1 (de) | Tace inhibitoren | |
| ATE432936T1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| UA85087C2 (en) | Monocyclic heterocycles as kinase inhibitors | |
| ATE527264T1 (de) | Kondensierte heterozyklische verbindungen als hemmer von proteinkinasen | |
| UA85701C2 (ru) | Способ получения ингибиторов триптазы | |
| EA200701813A1 (ru) | Новые амидозамещенные 6-фенилфенантридины | |
| EA200801211A1 (ru) | Производные 9-хлор-15-простагландина, способ их получения и использования в лекарственных препаратах |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1631295 Country of ref document: EP |